Phase Ib FAVOUR Trial
FAVOUR: Phase Ib Study of Furmonertinib in EGFR Exon 20 Insertion–Positive Locally Advanced or Metastatic NSCLC

Released: September 14, 2023

Activity

Progress
1
Course Completed